A recent study authored by Besli et al. (2025) has synthesized a range of novel multi-target compounds acting as dual acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitors with complementary antioxidant functions, to be suggested as potential therapeutics for Alzheimer’s disease management, in which deep in silico investigations were carried out to evaluate the efficacy of these novel pyrazole and benzofuran-based derivatives, which were sufficiently examined using both in vitro and in vivo assays. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.